Analyst Reco. Moderna, Inc.

Stocks

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 12/06/2026 BST			After hours 01:00:00
49.91 ^USD	+0.54%		49.02	-1.78%

06-09	Moderna, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-09-2026 03:20 PM
06-09	What Bundibugyo Ebola vaccines and treatments are under development	RE

Analyst Reco.

05-12	MODERNA : Jefferies reiterates its Neutral rating	ZD
05-04	Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says	MT
05-04	UBS Adjusts Price Target on Moderna to $45 From $36, Maintains Neutral Rating	MT
05-04	RBC Raises Price Target on Moderna to $38 From $35, Keeps Sector Perform Rating	MT
05-01	Morgan Stanley Raises Moderna Price Target to $33 From $30	MT
04-17	Goldman Sachs Adjusts Moderna Price Target to $43 From $41, Maintains Neutral Rating	MT
04-15	Jefferies Adjusts Price Target on Moderna to $45 From $37, Maintains Hold Rating	MT
04-14	Leerink Partners Adjusts Moderna PT to $21 From $12, Maintains Underperform Rating	MT
04-07	RBC Adjusts Price Target on Moderna to $35 From $30, Maintains Sector Perform Rating	MT
04-01	Barclays Adjusts Price Target on Moderna to $48 From $25, Maintains Equalweight Rating	MT
03-18	Deutsche Bank Adjusts Moderna Price Target to $45 From $28, Maintains Hold Rating	MT
03-05	Berenberg Raises Price Target on Moderna to $45 From $32, Keeps Hold Rating	MT
02-27	Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating	MT
02-17	Bernstein Adjusts Price Target on Moderna to $45 From $35, Maintains Market Perform Rating	MT
02-17	RBC Capital Adjusts Price Target on Moderna to $30 From $25, Maintains Sector Perform Rating	MT
02-13	RBC Raises Price Target on Moderna to $30 From $25, Keeps Sector Perform Rating	MT
02-13	Jefferies Raises Price Target on Moderna to $37 From $30	MT
02-11	Leerink Partners Adjusts Moderna PT to $12 From $17, Maintains Underperform Rating	MT
01-30	Leerink Partners Adjusts Moderna Price Target to $17 From $18, Maintains Underperform Rating	MT
01-29	TD Cowen Adjusts Moderna Price Target to $40 From $25, Maintains Hold Rating	MT
01-28	Wolfe Adjusts Price Target on Moderna to $25 From $17, Maintains Underperform Rating	MT
01-23	Bernstein Adjusts Price Target on Moderna to $35 From $25, Maintains Market Perform Rating	MT
01-12	Goldman Sachs Adjusts Price Target on Moderna to $36 From $33, Maintains Neutral Rating	MT
01-07	UBS Downgrades Moderna to Neutral From Buy, Cuts Price Target to $34 From $40	MT
01-06	BofA Adjusts Price Target on Moderna to $24 From $21, Maintains Underperform Rating	MT